drugset
drugset / Trial / NCT03486067

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

NCT03486067 ↗

Phase 1 Terminated 183 enrolled Celgene Corporation
NaSingle-groupOpen-labelTreatment

Summary

Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.

Timeline

Start
2018-04-03
Primary completion
2025-03-18
Completion
2025-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Alnuctamab Protein / enzyme biologic — Intravenous

Indications

plasma cell myeloma